[Investigation on radiosensitizing and tumor inhibiting actions of the antioxidant MTDQ (6,6'-methylen-bis/2,2,4-trimethyl-1-1,2-dihydroquinolin) (author's transl)].

Abstract

Unlike the hitherto known antioxidants, MTDQ is not a radiation protective-but a radiation sensitizing agent. According to autoradiographic findings accumulation of 14C-labelled MTDQ occurs in tumor tissue. The compound was found to be suitable in the combined treatment (MTDQ and 300 R x-ray therapy). In these instances tumor weight of solid Ehrlich- and Yoshida-tumors will be reduced even by doses ineffective as monotherapy. The MTDQ pretreatment of NKLy ascites tumorbearing rats raised survival rat by 60 to 90 per cent (controls 20%) and inhibited growth of solid Yoshida-tumors. No side-effects have been observed. In contrast to other antineoplastic agents MTDQ does not induce granulocytopenia.

• Authors: V Bär, G Foris, V Erdélyi, Z Pollák, S Eckhardt
• Journal: Archiv fur Geschwulstforschung (Arch Geschwulstforsch) Vol. 45 Issue 5 Pg. 489-95 ( 1975) ISSN: 0003-911X [Print] Germany
• Vernacular Title: Untersuchung der radiosensibilisierenden und tumorhemmenden Wirkung des als MTDQ (6,6' methylen bis/2,2,4-trimethyl-1,2-dihydroquinolin) bezeichneten antioxidans
• PMID: 1212067 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Antioxidants
• Quinolines
• Radiation-Sensitizing Agents
• 6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)

Topics

• Animals
• Antineoplastic Agents
• Antioxidants (pharmacology)
• Carcinoma, Ehrlich Tumor (drug therapy)
• Female
• Male
• Mice
• Neoplasm Transplantation
• Quinolines (pharmacology)
• Radiation-Sensitizing Agents
• Sarcoma, Yoshida (drug therapy)